Todd Foley
InvestorManaging Director at MPM BioImpact · Managing Director at MPM Capital
Boston, Massachusetts
FoundedAktis OncologyChiasmaClinical inkCrossbow TherapeuticsEntrada Therapeutics, Inc.Moat Biotechnology
About
Managing Director who joined the firm in 1999. Serves as Chairman of multiple portfolio company boards and has guided significant M&A outcomes including Semma Therapeutics acquisition by Vertex for $950M and Selexys acquisition by Novartis for $665M.
Experience
- MPM BioImpactManaging Directorcurrent1999 — present
- GenentechBusiness Development Intern1998
- Arthur D. LittleAnalyst1994 — 1997
Education
- Harvard Business SchoolMBA1997 — 1999
- Massachusetts Institute of TechnologyBS, Chemistry1990 — 1994
- Guilford High Schoolhigh school1986 — 1990
Skills & more
From Todd's professional profile.
Same school
Also attended Harvard Business School1,854
+ 1,848 more
Also attended Massachusetts Institute of Technology989
+ 983 more
Shared employers
Also worked at Genentech90
+ 84 more
Also worked at Arthur D. Little41
+ 35 more
Deals · 7
Moat BiotechnologyBoard seat
via MPM BioImpact · filed Oct 2025 · $15.6M raise
Crossbow TherapeuticsBoard seat
via MPM BioImpact · filed Sep 2025 · $80M raise
Firefly Bio, Inc.Board seat
via MPM BioImpact · filed Mar 2024 · $72M raise
Entrada Therapeutics, Inc.Board seat
via MPM BioImpact · filed Apr 2021 · $116.2M raise
HotKnot Therapeutics, Inc.Board seat
via MPM BioImpact · filed Feb 2021 · $72M raise
Tetherex Pharmaceuticals CorpBoard seat
via MPM BioImpact · filed Dec 2020
Clinical inkBoard seat
via MPM BioImpact · filed Dec 2017 · $2.5M raise
Attribution from SEC filings, press coverage, and firm rosters.




















